Article
Gastroenterology & Hepatology
Markus F. Neurath, Michael Vieth
Summary: Mucosal healing is an important prognostic factor in the management of patients with inflammatory bowel disease. It can predict clinical remission and resection-free survival. There are two levels of mucosal healing: endoscopic healing and histological healing. Drug therapies and new techniques can have an impact on mucosal healing, but cannot provide a definitive cure.
Article
Biochemistry & Molecular Biology
Keiko Maeda, Masanao Nakamura, Takeshi Yamamura, Tsunaki Sawada, Eri Ishikawa, Akina Oishi, Shuji Ikegami, Naomi Kakushima, Kazuhiro Furukawa, Tadashi Iida, Yasuyuki Mizutani, Takuya Ishikawa, Eizaburo Ohno, Takashi Honda, Masatoshi Ishigami, Hiroki Kawashima
Summary: This study analyzed the usefulness of serum gelsolin as a serological biomarker for clinical and endoscopic activities in ulcerative colitis. The findings indicate that serum gelsolin level correlates with clinical and endoscopic activities in ulcerative colitis, has higher sensitivity and specificity than C-reactive protein, and can detect mucosal healing, suggesting its potential as a biomarker for ulcerative colitis.
Article
Biochemistry & Molecular Biology
Leonie Wittner, Lukas Wagener, Jakob J. Wiese, Iris Stolzer, Susanne M. Krug, Elisabeth Naschberger, Rene Jackstadt, Rudi Beyaert, Raja Atreya, Anja A. Kuehl, Gregor Sturm, Miguel Gonzalez-Acera, Jay V. Patankar, Christoph Becker, Britta Siegmund, Zlatko Trajanoski, Beate Winner, Markus F. Neurath, Michael Schumann, Claudia Guenther
Summary: The paracaspase MALT1 plays a crucial role in mucosal inflammation. It is highly expressed in colonic epithelial cells of UC patients and experimental colitis. Mechanistically, MALT1 protease function inhibits ferroptosis and contributes to NF-kappa B signaling and STAT3 signaling, which are involved in inflammation and tissue healing.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Tao He, Lei Zong, Peng Pan, Shanming Sun, Hongmei Qu
Summary: This study found that NBI endoscopic MVP staging has better predictive value for histological healing and clinical recurrence status in patients with UC compared to white light endoscopy. There is a significant correlation between NBI endoscopic MVP staging and clinical outcomes, showing its potential as a useful tool in assessing disease progression in UC patients.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Liliana Lykowska-Szuber, Michal Walczak, Marzena Skrzypczak-Zielinska, Joanna Suszynska-Zajczyk, Kamila Stawczyk-Eder, Katarzyna Waszak, Piotr Eder, Anna Wozniak, Iwona Krela-Kazmierczak, Ryszard Slomski, Agnieszka Dobrowolska
Summary: Crohn's disease patients who do not respond to anti-TNF therapy may have alterations in the expression levels of specific genes, particularly TNFRSF1B, FCGR3A, and IL1B. This can be predicted by functional analysis in colon biopsies and cell culture models.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Peiyao Wu, Siyu Yao, Xing Wang, Long Yang, Siling Wang, Wenbing Dai, Hua Zhang, Bing He, Xueqing Wang, Shujun Wang, Qiang Zhang
Summary: This study developed orally administrated IND nanoparticles (IND-NPs) for the treatment of ulcerative colitis (UC) and investigated their functions and mechanisms in cellular and animal inflammatory models. The IND-NPs were found to improve UC-associated symptoms, inhibit inflammatory response, and preserve intestinal barrier integrity through regulating intercellular junctions and restoring mitochondrial dysfunction, showing a promising potential in UC treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Gastroenterology & Hepatology
Marina Liso, Giulio Verna, Elisabetta Cavalcanti, Stefania De Santis, Raffaele Armentano, Angela Tafaro, Antonio Lippolis, Pietro Campiglia, Antonio Gasbarrini, Mauro Mastronardi, Theresa Torres Pizarro, Fabio Cominelli, Loris Riccardo Lopetuso, Marcello Chieppa
Summary: This study provides new insights and alternative approaches to treat ulcerative colitis (UC) patients. It suggests that anti-interleukin (IL)1 strategies, such as anakinra, may be a more effective therapeutic option for primary nonresponders to anti-tumor necrosis factor (TNF) therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Eduardo J. Villablanca, Katja Selin, Charlotte R. H. Hedin
Summary: Current treatments for inflammatory bowel disease (IBD) mainly focus on inhibiting inflammation, but the use of immunosuppressive therapy can lead to infectious and neoplastic diseases. Therefore, finding a way to achieve mucosal healing without immunosuppression is important. The lack of treatments that directly promote mucosal healing and regeneration in IBD may be due to a lack of understanding of the underlying pathways. Stem cells, growth factors, and organoid culture and stem cell therapy are potential novel mechanisms to restore barrier function in IBD.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Cristian Hernandez-Rocha, Shadi Nayeri, Williams Turpin, Mike Steel, Krzysztof Borowski, Joanne M. Stempak, James Conner, Mark S. Silverberg
Summary: This study aimed to establish the prognosis, transcriptional and microbial features of histo-endoscopic remission and activity in ulcerative colitis (UC) patients. The results showed that UC patients with histo-endoscopic remission had a lower risk of relapse and their rectosigmoid mucosa transcriptional profile resembled that of healthy controls. Host genes with antimicrobial properties were significantly associated with mucosal microbiota.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Yuki Horio, Motoi Uchino, Masataka Igeta, Kentaro Nagano, Kurando Kusunoki, Ryuichi Kuwahara, Kei Kimura, Kozo Kataoka, Naohito Beppu, Masataka Ikeda, Hiroki Ikeuchi
Summary: This study investigated the risk factors for recurrent ulcerative colitis-associated colorectal cancer (UC-CRC). The significant risk factors for recurrence were age at surgery, undifferentiated carcinoma, lymph node metastasis, and vascular invasion. Young adult patients with stage III CRC had a worse prognosis.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2023)
Article
Medicine, General & Internal
Fang Chen, Yue Hu, Yi-Hong Fan, Bin Lv
Summary: This study demonstrated the clinical significance of fecal calprotectin in evaluating endoscopic patterns and clinical manifestation in ulcerative colitis patients. The cut-off value of 164 μg/g for FC concentration was found to predict clinical active disease with high sensitivity and specificity. However, further large-scale studies are needed to confirm the reliability of the cut-off value.
FRONTIERS IN MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Lorenzo Bertani, Brigida Barberio, Marco Fornili, Luca Antonioli, Federico Zanzi, Cesare Casadei, Laura Benvenuti, Sonia Facchin, Vanessa D'Antongiovanni, Greta Lorenzon, Linda Ceccarelli, Laura Baglietto, Nicola de Bortoli, Massimo Bellini, Francesco Costa, Edoardo Vincenzo Savarino, Matteo Fornai
Summary: This study suggests that serum oncostatin M is a drug-specific biomarker that can be used to predict therapeutic effectiveness in anti-TNF treatment. These results emphasize the utility of serum oncostatin M measurement in patients treated with anti-TNF.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Kana Shiraishi, Shinya Furukawa, Sen Yagi, Kenichirou Mori, Tomoyuki Ninomiya, Keitarou Kawasaki, Yuji Mizukami, Seiyuu Suzuki, Masayoshi Uraoka, Naozumi Shibata, Sanae Nakamura, Satoshi Imamine, Hidehiro Murakami, Katsuhisa Ohashi, Masamoto Torisu, Makoto Yano, Aki Hasebe, Harumi Yano, Masato Murakami, Eiji Takeshita, Yoshio Ikeda, Yoichi Hiasa
Summary: In patients with ulcerative colitis, serum globulin showed a significant positive association with endoscopic activity and a significant inverse association with mucosal healing, especially in the low C-reactive protein group.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Sun-Ho Lee, Margaret Walshe, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Tomer Greener, Adam Weizman, Mark S. Silverberg, Byong Duk Ye
Summary: The study suggests that changes in serum albumin levels within the first 2 weeks of anti-TNF treatment can predict primary nonresponse, endoscopic outcomes, time to colectomy, and anti-TNF failure in patients with UC. Early access to this biomarker may help identify patients at risk of treatment failure and guide early optimization of anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Inca, Marco Astegiano, Walter Fries, Monica Milla, Carolina Ciacci, Fernando Rizzello, Simone Saibeni, Rachele Ciccocioppo, Ambrogio Orlando, Fabrizio Bossa, Mariabeatrice Principi, Piero Vernia, Chiara Ricci, Maria L. Scribano, Giorgia Bodini, Dario Mazzucco, Gabrio Bassotti, Gabriele Riegler, Andrea Buda, Matteo Neri, Flavio Caprioli, Fabio Monica, Aldo Manca, Erica Villa, Gionata Fiorino, Michele Comberlato, Nicola Aronico, Cristina Della Corte, Roberta Caccaro, Paolo Gionchetti, Paolo Giuffrida, Paola Iovino, Marco Lenti, Caterina Mengoli, Lucienne Pellegrini, Alberto Pieraccini, Davide Ribaldone, Anna Testa, Cristina Ubezio, Anna Viola, Maurizio Vecchi, Catherine Klersy, Antonio Di Sabatino
Summary: The prevalence of anemia in Italian IBD patients is lower than previously reported, with the majority being caused by iron deficiency and leading to fatigue and decreased quality of life. However, a large proportion of patients with iron and/or vitamin deficiencies remain untreated.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Ferdinando D'Amico, Olga Tasopoulou, Gionata Fiorino, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Pierpaolo Sileri, Antonino Spinelli, Laurent Peyrin-Biroulet, Silvio Danese
Summary: This study aimed to investigate the impact of postoperative biological therapy on the incidence of endoscopic recurrence and long-term outcomes in Crohn's disease patients. The results showed that early treatment with biologics decreased the rates of endoscopic recurrence and hospitalization/surgery.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Torsten Kucharzik, Rune Wilkens, Maria-Antonietta D'agostino, Giovanni Maconi, Manuela Le Bars, Marjolein Lahaye, Ivana Bravata, Maciej Nazar, Lioudmila Ni, Elena Ercole, Mariangela Allocca, Nadezda Machkova, Floris A. E. de Voogd, Carolina Palmela, Rose Vaughan, Christian Maaser
Summary: In this study, ustekinumab was found to be effective in reducing bowel inflammation in patients with moderate-to-severe Crohn's disease. The use of intestinal ultrasound as a noninvasive imaging procedure provided valuable insights into the treatment response. Colonic involvement and biologic-naive status were associated with better outcomes.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Mariella Mannino, Giuseppe Rizzo, Ambrogio Orlando
Summary: The study investigated the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) treated with immunomodulatory or biological drugs. The majority of IBD patients showed seropositivity after COVID-19 vaccination, but the magnitude of the humoral response was significantly lower compared to healthy controls. These findings suggest that the lower response is mostly unrelated to the use of immune-modifying treatments.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Joana Torres, Maria Chaparro, Mette Julsgaard, Konstantinos Katsanos, Zuzana Zelinkova, Manasi Agrawal, Sandro Ardizzone, Marjo Campmans-Kuijpers, Gabriele Dragoni, Marc Ferrante, Gionata Fiorino, Emma Flanagan, Catarina Frias Gomes, Ailsa Hart, Charlotte Rose Hedin, Pascal Juillerat, Annemarie Mulders, Par Myrelid, Aoibhlinn O'Toole, Pauline Riviere, Michael Scharl, Christian Philipp Selinger, Elena Sonnenberg, Murat Toruner, Jantien Wieringa, C. Janneke Van der Woude
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Paolo Angelo Cortesi, Gionata Fiorino, Laurent Peyrin-Biroulet, Lorenzo Giovanni Mantovani, Vipul Jairath, Kristine Paridaens, Fredrik L. Andersson, Silvio Danese
Summary: This study assessed the cost-effectiveness of a treat-to-target strategy based on clinical signs and faecal calprotectin levels in patients with mild-moderate ulcerative colitis. The results showed that this approach increased the time spent in clinical remission and reduced the number of relapses compared to a strategy based solely on symptoms. However, it was also associated with higher costs.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Paolo Angelo Cortesi, Gionata Fiorino, Lorenzo Giovanni Mantovani, Silvio Danese
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Dermatology
Giorgio Stabile, Stefania Guida, Maria Angela Allocca, Silvio Danese, Franco Rongioletti
AMERICAN JOURNAL OF DERMATOPATHOLOGY
(2023)
Editorial Material
Dermatology
Giorgio Stabile, Stefania Guida, Maria Angela Allocca, Silvio Danese, Franco Rongioletti
AMERICAN JOURNAL OF DERMATOPATHOLOGY
(2023)
Review
Pharmacology & Pharmacy
Alexander Goetsch, Ferdinando D'Amico, Mariangela Allocca, Gionata Fiorino, Federica Furfaro, Alessandra Zilli, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese
Summary: JAK inhibitors are emerging small-molecule drugs used for the treatment of ulcerative colitis and other immune mediated inflammatory diseases. They are orally bioavailable, have a rapid mechanism of action, and are non-immunogenic. Special attention should be given to elderly patients or those with cardiovascular or oncological risk factors, and JAK inhibitors should only be recommended when no alternatives are available. JAK inhibitors also have the potential to be combined with other drugs for the management of difficult-to-treat cases.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Luca Massimino, Orazio Palmieri, Amanda Facoetti, Davide Fuggetta, Salvatore Spano, Luigi Antonio Lamparelli, Silvia D'Alessio, Stefania Cagliani, Federica Furfaro, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Daniele Noviello, Anna Latiano, Fabrizio Bossa, Tiziana Latiano, Alessandra Pirola, Luca Mologni, Rocco Giovanni Piazza, Danilo Abbati, Francesco Perri, Chiara Bonini, Laurent Peyrin-Biroulet, Alberto Malesci, Vipul Jairath, Silvio Danese, Federica Ungaro
Summary: This study found that the virome-associated protein encoded by the hepatitis B virus (HBx) is detected in about 45% of patients with ulcerative colitis (UC) and is associated with UC progression. Experimental findings showed that HBx induces colonic inflammation and its silencing reverses the colitis phenotype. HBx acts as a transcriptional regulator in epithelial cells, leading to barrier leakage and altering mucosal immunity. This study provides a new perspective on targeted treatments for the virome composition of the gut microbiota.
Article
Gastroenterology & Hepatology
Antonio Rispo, Giulio Calabrese, Anna Testa, Nicola Imperatore, Marta Patturelli, Mariangela Allocca, Alessia Dalila Guarino, Nicola Mattia Cantisani, Benedetta Toro, Fabiana Castiglione
Summary: Hand-held intestinal ultrasound and conventional intestinal ultrasound are comparable in defining ulcerative colitis extension and evaluating Milan Ultrasound Criteria. Hand-held intestinal ultrasound could be reliable for detecting disease activity and estimating its extension, providing close monitoring. It also represents a non-invasive, easily practicable investigation, allowing immediate medical decisions with significant time and cost advantages.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Acoustics
Mariangela Allocca, Arianna Dal Buono, Silvia D'Alessio, Paola Spaggiari, Valentina Garlatti, Antonino Spinelli, Francesco Faita, Silvio Danese
Summary: This study aimed to assess the relationships between intestinal ultrasound parameters and histopathologic findings in patients with Crohn's disease undergoing surgery. The results showed that ultrasound had high sensitivity, specificity, and accuracy in detecting stricturing and penetrating complications. There was a strong correlation between ultrasound measurements and histological measurements of wall thickness.
JOURNAL OF ULTRASOUND IN MEDICINE
(2023)
Review
Medicine, General & Internal
Sarah Bencardino, Ferdinando D'Amico, Ilaria Faggiani, Francesca Bernardi, Mariangela Allocca, Federica Furfaro, Tommaso Lorenzo Parigi, Alessandra Zilli, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Summary: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects patients' quality of life. There is a need for new drugs that target new pathways and minimize adverse events. Sphingosine-1-phosphate (S1P) receptor modulators have shown promise in reducing inflammation in UC by controlling the movement of immune cells. Several S1P receptor modulators, including ozanimod, etrasimod, and VTX002, have been developed and tested in UC. Oral administration, rapidity, and safety profile are the advantages of these drugs.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Laura Cantoro, Rita Monterubbianesi, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Mariangela Allocca, Rocco Cosintino, Roberto Faggiani, Silvio Danese, Gionata Fiorino
Summary: Delayed diagnosis poses a challenge to managing inflammatory bowel disease (IBD), especially in Crohn's disease (CD). The Red Flags Index score, along with non-invasive biomarkers like fecal calprotectin, can effectively reduce diagnostic delay and aid in early treatment strategies for patients with IBD.
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
